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ubgroup or Selection Bias?
atriuretic peptide testing has achieved an important role in
ardiology and particularly in heart failure (HF) (1,2). After
iagnostic and prognostic benefits have been proven, clinicians
ave been intrigued with its potential for patient clinical
anagement (3).
After 10 years of research and the publication of several
andomized trials, including the BATTLESCARRED (NT-
ro-BNP-Assisted Treatment To LEssen Serial Cardiac Read-
issions and Death) trial (4), natriuretic peptides are still
aught in “no-man’s land.” Although some benefits were
vident, the applicability to clinical practice remains question-
ble. In the BATTLESCARRED trial, only 998 (28%) patients
f 3,576 screened met the inclusion criteria, and 364 patients, or
pproximately 10% of the initial cohort, were finally random-
zed. It is also important to note that mortality was lower than
xpected in a hospitalized HF cohort. Along with this, the
ong-term benefit was observed only for patients 75 years of age
r younger, which is roughly the median age in an average HF
opulation (5).
When scrutinizing the reported trials, some other reasons for
he results obtained herein may be relevant. Instead of fishing
or statistical significance in subgroup analysis, it may be more
elevant to switch gears and test natriuretic peptides in settings
here most patients are managed and good clinical practice
annot be implemented as appropriate for various clinical and
ogistical reasons. The BATTLESCARRED trial, as well as
any other trials, already demonstrated that there is an impor-
ant gap between specialized HF settings and usual care
ettings. It has also been shown that natriuretic peptides may
revent unnecessary referrals from primary care (6). Along with
rimary care settings, patients with HF and preserved left
entricular ejection fraction may be 2 major fields of interest.
ext to that, natriuretic peptide-guided discharge and the
ddition of natriuretic peptide testing in patients with only
orderline indications for mechanical devices may prevent
ospitalizations. However, as clinicians, we always have to keep
n mind that we are managing patients and not laboratory
ndings (7), and no biomarker will ever replace experienced
linical judgment. Although the BATTLESCARRED trial did
ot make the final step on its mission, we firmly believe other
ridges with public health implications can be crossed. Whether
e are on point or whether we also failed will be judged in
uture. cMitja Lainscak, MD, PhD
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Question of Central Importance
omaschitz et al. (1) reported associations between plasma
ldosterone/renin ratio (ARR) and blood pressure (BP) in a
ohort of patients undergoing coronary artery angiography. A
ovel aspect of this study was assessment of both brachial and
ortic (central) BP. The focus on the risk related to BP remains
n conventional brachial cuff BP values. However, large differ-
nces (e.g., 30 mm Hg) in central systolic blood pressure
SBP) may occur between individuals with similar brachial SBP
2,3). The clinical implications of this central-to-peripheral BP
ifference was highlighted in a recent meta-analysis in which
entral BP indexes predicted cardiovascular events and mortal-
ty independent of brachial BP (4). Given that homeostatic
ontrol of blood volume and BP are dependent on central
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October 26, 2010:1514–6ensing mechanisms (i.e., renal perfusion), stronger correlations
etween ARR and central BP, compared with brachial BP, may
e expected. This was not observed in the Tomaschitz et al. (1)
tudy.
With each cardiac ejection, there is generation of forward
raveling pressure waves that move at high speed (e.g., 5 to 20 m/s)
rom proximal elastic large arteries (e.g., the aorta and carotid
rtery) distally through increasingly less compliant vasculature
e.g., the brachial and radial arteries). Some of these waves are
eflected back to the heart. Overall, the result is amplification of
he pressure pulse such that central SBP is always lower than
rachial SBP, whereas brachial diastolic blood pressure (DBP)
emains similar or is slightly lower (e.g., 1 to 3 mm Hg) than
entral DBP (5). In patient populations similar to that reported by
omaschitz et al. (1), directly recorded central SBP is expected to
e approximately 10 to 17 mm Hg lower than peripheral SBP
6,7), but this is not the case as presented by Tomaschitz et al. (1).
ndeed, in places throughout the text, brachial SBP is lower than
entral SBP and central DBP is up to 10 mm Hg lower than
rachial DBP.
What explains this nonphysiologic discordance between bra-
hial and central BP? Could this be a result of different method-
logies and time points at which brachial and central BPs were
cquired? For correct data interpretation, this requires clarification.
n any case, perhaps the relationship between ARR and central and
rachial BP may be best explored using noninvasive central BP
ethods combined with traditional upper arm BP. This approach
lso would enable scrutiny of the relationship between BP ampli-
cation and ARR and, importantly, would negate the confounding
ffects associated with measuring BP in the coronary catheteriza-
ion laboratory.
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e thank Dr. Sharman for his interest in our paper regarding the
ssociations of the aldosterone-to-renin ratio with arterial blood
ressure (BP) (1). We appreciate his insightful comments on the
ifferences between peripheral and central BP levels in the LURIC
Ludwigshafen Risk and Cardiovascular Health) study.
Dr. Sharman correctly stated that systolic BP, as the pulsatile
omponent of BP, is amplified with increasing distance from the
ortic root, resulting in higher peripheral than corresponding
entral BP levels. In fact, in LURIC we observed slightly lower
eripheral systolic BP levels (141  24 mm Hg) that were
easured on the morning of the day when coronary angiography
as scheduled (and that constituted the mean of 3 measurements),
han central aortic systolic BP values (143 30 mm Hg) that were
etermined invasively once during routine diagnostic cardiac cath-
terization later in the day. Peripheral diastolic BP measurements
81  11 mm Hg) were higher than aortic diastolic BP levels
71  12 mm Hg), and here the same limitations apply regarding
requency and timing of the 2 measurements.
The pressure amplification phenomenon generally is more
ronounced in the younger age group and diminishes with aging
ecause of the development of progressive aortic stiffening (2). The
URIC cohort represents an elderly population, presumably with
ncreased mean vascular stiffness, as can be deduced from the large
ercentage of participants exhibiting coronary artery disease (78%).
e therefore believe that in addition to the above considerations,
less pronounced pressure amplification might have accounted for
he differences seen in diastolic BP levels. Furthermore, ongoing
ntihypertensive drug treatment, which was noted for 86.8% of the
URIC participants, additionally might have influenced the rela-
ionship between central and peripheral BP values because periph-
ral BP measurements were obtained earlier in the day than
nvasive BP measurements (2).
We agree with Dr. Sharman that noninvasive measurements of
entral BP are an appropriate approach. However, it has been
ecommended in a consensus document pertaining to central BP
easurements that central BP ideally should be determined
nvasively (3). Although it has been shown that noninvasive, that
s, tonometric, methods also may measure central BP accurately,
naccurate measurement of cuff pressure, heart rate, height, age,
ngoing medication, and observer-dependent factors may consti-
ute important confounders of this method (3,4). We therefore
elieve that invasive central BP measurement during cardiac
atheterization was a reliable method for estimating aortic BP
alues, despite the fact that the scheduling of peripheral and aortic
P measurements at 2 different time points was suboptimal. We
evertheless found it important to report both central and periph-
ral BP datasets to demonstrate that there is a strong relationship
etween the aldosterone-to-renin ratio and BP, independent of the
ethod used for measurement of BP. The concordant finding with
oth methods strengthens our findings and underlines the impor-
ant role of inappropriate aldosterone levels in the pathogenesis of
rterial hypertension and cardiovascular disease (5,6).
